• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners

    3/12/25 6:30:00 AM ET
    $CNTG
    Medical Specialities
    Health Care
    Get the next $CNTG alert in real time by email

    CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 12, 2025 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC:CNTGF) ("CENTOGENE" or the "Company") today announced it has closed its transaction to sell its operating subsidiaries to an affiliate of Charme Capital Partners Limited ("Charme").

    As announced on November 13, 2024, the Company had entered into definitive agreements with Charme for the sale of 100% ownership in Centogene GmbH, CENTOGENE's sole operating subsidiary, certain intercompany receivables, and assumption of the Company's loan granted by Oxford Finance LLC (the "Transaction").

    On December 4, 2024, the Company held an Extraordinary General Meeting ("EGM") in connection with the Transaction, where shareholders voted in favor of all proposals.

    Following the closing of the Transaction, the Company and its remaining subsidiary, Centogene Switzerland AG, will no longer have any operations. The Company intends to liquidate Centogene Switzerland AG, and the Company will enter dissolution and liquidation in accordance with the laws of the Netherlands and its organizational documents with effect from the consummation of the Transaction as resolved upon by its shareholders at the EGM.

    It is currently expected that the Company will make a liquidation distribution to its shareholders. The exact liquidation distribution, if any, will take into account the Company's anticipated running costs through the finalization of the liquidation and any reserves the Company may establish to satisfy expenses and other liabilities and to comply with applicable law. The exact record date and payment date of the liquidation distribution, if any, will be communicated by the Company on its investor website when available. The Company's reporting obligations under the U.S. Securities Exchange Act have been suspended and the Company expects that its securities will cease to be quoted on the OTC market.

    INVESTORS ARE ENCOURAGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE MATERIALS MADE AVAILABLE TO SHAREHOLDERS IN CONNECTION WITH THE EGM AND THE FORM 6-K FILED ON NOVEMBER 13, 2024, AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE TRANSACTION AND RELATED MATTERS.

    This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities in Centogene N.V. This announcement is not for release, publication, or distribution, in whole or in part, in or into, directly or indirectly, in any jurisdiction in which such release, publication or distribution would be unlawful.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "continues," "expect," "estimate," "intend," "project," "plan," "is designed to," "potential," "predict," "objective" and similar expressions and future or conditional verbs such as "will," "would," "should," "could," "might," "can," and "may," or the negative of these are generally intended to identify forward-looking statements. Forward-looking statements may include statements regarding the amount of funds (if any) from the Transaction available to pay to the Company's stockholders in a liquidation distribution, the Company's plans liquidate and dissolve, and any assumptions underlying any of the foregoing. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause CENTOGENE's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, (i) the amounts that will need to be set aside as reserves by the Company being higher than anticipated; (ii) potential unknown contingencies or liabilities and the Company's ability to resolve them; (iii) the outcome of any legal proceedings related to the Transaction, the dissolution and liquidation of the Company or its subsidiaries or otherwise, (iv) economic, business and/or competitive factors that may adversely affect the Company, (v) negative economic and geopolitical conditions and instability and volatility in the worldwide financial markets, (vi) possible changes in current and proposed legislation, regulations and governmental policies, (vii) the Company's ability to streamline cash usage and (viii) the Company's continued ongoing compliance with covenants linked to financial instruments. For further information on the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to CENTOGENE's business in general, see CENTOGENE's risk factors set forth in CENTOGENE's Form 20-F filed on May 15, 2024, with the SEC and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and CENTOGENE specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

    CONTACT

    Communications

    [email protected]

    Investor Relations

    [email protected]  



    Get the next $CNTG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNTG

    DatePrice TargetRatingAnalyst
    8/5/2021$14.00Outperform
    Credit Suisse
    More analyst ratings

    $CNTG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 12, 2025 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC:CNTGF) ("CENTOGENE" or the "Company") today announced it has closed its transaction to sell its operating subsidiaries to an affiliate of Charme Capital Partners Limited ("Charme"). As announced on November 13, 2024, the Company had entered into definitive agreements with Charme for the sale of 100% ownership in Centogene GmbH, CENTOGENE's sole operating subsidiary, certain intercompany receivables, and assumption of the Company's loan granted by Oxford Finance LLC (the "Transaction"). On December 4, 2024, the Company held an Extraordinary General Meeting ("EGM") in connection with th

      3/12/25 6:30:00 AM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE Announces Voting Results of Extraordinary General Meeting

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC:CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company's Extraordinary General Meeting. Shareholders voted in favor of all proposals, which included the approval of the previously announced envisaged sale and transfer of Centogene GmbH to Charme Capital Partners Limited, a pan-European private equity firm. At the Extraordinary General Meeting of CENTOGENE, 57.16% of the Company's issued share capital were represented. About CENTOGENE CENTOGENE's mi

      12/4/24 7:51:01 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC:CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has concluded its strategic review process and has entered into a Share Purchase Agreement ("SPA") pursuant to which its operating subsidiaries will be sold to an affiliate of Charme Capital Partners Limited ("Charme"), a pan-European private equity firm, for a cash purchase price of EUR 8,717,906.80. In connection with the transaction, Centogene GmbH will receive funding, secured by Saudi accounts receivables, from its Saudi Arabian

      11/13/24 6:30:01 AM ET
      $CNTG
      Medical Specialities
      Health Care

    $CNTG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Credit Suisse resumed coverage on Centogene with a new price target

      Credit Suisse resumed coverage of Centogene with a rating of Outperform and set a new price target of $14.00

      8/5/21 6:17:32 AM ET
      $CNTG
      Medical Specialities
      Health Care
    • Credit Suisse reiterated coverage on Centogene with a new price target

      Credit Suisse reiterated coverage of Centogene with a rating of Outperform and set a new price target of $14.00 from $15.00 previously

      6/17/21 7:44:42 AM ET
      $CNTG
      Medical Specialities
      Health Care

    $CNTG
    Leadership Updates

    Live Leadership Updates

    See more
    • CENTOGENE Reports First Half 2023 Financial Results

      First half 2023 total revenues with double-digit growth of 15.1% at €24.6 millionBoth Pharma and Diagnostics segments deliver strong performance, reaffirming full year 2023 guidance for total revenue growth between 10% to 15%Recently announced strategic collaboration with Lifera, a biopharmaceutical company wholly-owned by the Saudi Arabia Public Investment Fund (PIF), strengthens global genomic and multiomic footprint and secures CENTOGENE $30 million investment and approx. $50 million in Joint Venture upfront payment and performance-related milestones CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), the essential life s

      9/7/23 5:00:52 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 30, 2023 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (NASDAQ:CNTG) (the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company's Annual General Meeting. Shareholders voted in favor of all proposals, which included the appointment of Prof. Dr. Peter Bauer as a member of the Management Board of the Company, as well as the appointment of Mary Sheahan and the reappointment of Peer Schatz as members of the Supervisory Board of the Company. The shareholders extended the period for drawing up the Dutch statutory annual accounts and board report f

      6/30/23 4:30:02 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE Reports Full Year 2022 Financial Results

      Full Year 2022 total revenues with double-digit growth of 12% at €47.5 million, in line with prior guidanceSignificant expansion of gross profit margin from 32% to 42% and ongoing cost control resulted in significant improvement of net resultsBoth Pharma and Diagnostics segments positioned for strong performance in 2023, guidance of FY2023 total revenue growth between 10% to 15% CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 16, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG) ("we" or the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2022,

      5/16/23 6:25:08 PM ET
      $CNTG
      Medical Specialities
      Health Care

    $CNTG
    SEC Filings

    See more
    • SEC Form 6-K filed by Centogene N.V.

      6-K - Centogene N.V. (0001757097) (Filer)

      8/19/24 7:37:31 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by Centogene N.V.

      6-K - Centogene N.V. (0001757097) (Filer)

      8/7/24 6:18:25 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • SEC Form 6-K filed by Centogene N.V.

      6-K - Centogene N.V. (0001757097) (Filer)

      8/1/24 4:15:59 PM ET
      $CNTG
      Medical Specialities
      Health Care

    $CNTG
    Financials

    Live finance-specific insights

    See more
    • CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results

      - Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance - Focus on Pharma and Diagnostics to Position for Strong Performance in 2022 - Closed $62 Million Financing Round and on Track to Exit COVID-19 Business - Management to Host Conference Call at 2 p.m. CET/8 a.m. ET Today CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 30, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021, and provided a business update. "2021 wa

      3/30/22 7:30:00 AM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it will issue its financial results for the quarter and full year ended December 31, 2021, on Wednesday, March 30, 2022, and will host a conference call and webcast to discuss these results at 2 p.m. CEST / 8 a.m. EDT that day. Participants may register in advance for the conference call and webcast to be held on March 30, 2022, at http://emea.directeventreg.com/registration/5737758. Upon registering, each participant will be provided w

      3/23/22 6:30:00 AM ET
      $CNTG
      Medical Specialities
      Health Care
    • CENTOGENE Reports Third Quarter 2021 Financial Results

      CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (NASDAQ:CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced financial results for the third quarter ended September 30, 2021, and provided a recent business update. Executive Commentary "We are encouraged by the progress achieved in Q3 on our continued path to return focus and growth to our rare disease business, driving strategic Core Business execution," stated Andrin Oswald, M.D., Chief Executive Officer at CENTOGENE. "We saw continued recovery trends in the Diagnostics segment, with over 40% incre

      11/24/21 7:35:47 AM ET
      $CNTG
      Medical Specialities
      Health Care

    $CNTG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Centogene N.V. (Amendment)

      SC 13D/A - Centogene N.V. (0001757097) (Subject)

      3/11/22 4:44:52 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Centogene N.V. (Amendment)

      SC 13D/A - Centogene N.V. (0001757097) (Subject)

      2/22/22 4:00:59 PM ET
      $CNTG
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Centogene N.V.

      SC 13G - Centogene N.V. (0001757097) (Subject)

      12/8/21 8:52:19 PM ET
      $CNTG
      Medical Specialities
      Health Care